Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 37.1
edited by manuelmenendez
on 2025/02/02 07:14
on 2025/02/02 07:14
Change comment:
There is no comment for this version
To version 47.1
edited by manuelmenendez
on 2025/03/03 22:46
on 2025/03/03 22:46
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,9 +2,9 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensional diagnostic framework for CNS diseases// = 5 += //A new tridimensional diagnostic framework for complex CNS diseases// = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 7 +This project is focused on developing a novel nosological and diagnostic framework for complex CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 8 We aim to create a structured, interpretable, and scalable diagnostic tool. 9 9 ))) 10 10 ))) ... ... @@ -17,31 +17,21 @@ 17 17 18 18 = **Overview** = 19 19 20 +The classification and diagnosis of central nervous system (CNS) diseases have long been constrained by traditional, phenotype-based approaches that often fail to capture the complex interplay of pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes. 20 20 21 - Theclassification anddiagnosisof central nervoussystem (CNS) diseaseshavelong been constrainedby traditionalphenotype-basedpproaches,whichoften failcapture the complexpathophysiologicalmechanisms,molecular biomarkers, andneuroanatomicalchanges thatdrivedisease progression.Neurodegenerative andpsychiatric disorders,forxample,exhibitsignificant clinicaloverlap,co-pathology, andheterogeneity, making currentdiagnosticmodelsinsufficient.22 +**Neurodiagnoses** redefines this landscape by integrating advanced AI with multi-modal data—including genetics, neuroimaging, biomarkers, and digital health records—to create a more precise, scalable, and data-driven diagnostic system. 22 22 23 - This projectproposesanewdiagnostic framework—onethat shifts fromsymptom-basedclassificationstoanetiology-driven,tridimensionalsystem. Byintegratinggenetics, proteomics, neuroimaging,computationalmodeling,andAI-poweredannotations,this approachaimsto providemore precise,scalable, and biologically groundedmethodfordiagnosingand managing CNS diseases.24 +Additionally, **Neurodiagnoses is now expanding into disease prediction and biomarker estimation**, integrating state-of-the-art machine learning models to enhance precision diagnostics and disease progression forecasting. 24 24 25 - The AI-powered annotationsystemplays a critical role by structuring, interpreting,and tracking multi-modal data, ensuringreal-time disease progression analysis, cliniciandecisionsupport, andpersonalized treatment pathways.26 +On this page, you will find: 26 26 27 -=== **Project Aim** === 28 +* Detailed descriptions of both the clinical diagnostic tools and the research framework. 29 +* Access to our AI models, data processing pipelines, and digital twin simulations. 30 +* Collaborative resources for researchers, clinicians, and AI developers. 31 +* Guidelines and instructions on how to contribute to and expand the project. 28 28 29 - Neurodiagnosesis an open-source AI-powered diagnostic system designed for complex central nervous system (CNS) disorders, including neurodegenerative diseases, autoimmune encephalopathies, prion disorders, and genetic syndromes.Theproject aims to develop a tridimensionaldiagnosticframeworkwith anAI-powered annotationsystem, integrating etiology, molecular biomarkers, and neuroanatomoclinical correlations for precise, standardized, and scalable CNS disease diagnostics.33 +== **The role of AI-powered annotation** == 30 30 31 -The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 32 - 33 -* **Axis 1**: Etiology (genetic or other causes of diseases). 34 -* **Axis 2**: Molecular Markers (biomarkers). 35 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 36 - 37 -This methodology enables: 38 - 39 -* Greater precision in diagnosis. 40 -* Integration of incomplete datasets using AI-driven probabilistic modeling. 41 -* Stratification of patients for personalized treatment. 42 - 43 -== **The Role of AI-Powered Annotation** == 44 - 45 45 To enhance standardization, interpretability, and clinical application, the framework integrates an AI-powered annotation system, which: 46 46 47 47 * Assigns structured metadata tags to diagnostic features. ... ... @@ -50,29 +50,33 @@ 50 50 * Improves AI model transparency through interpretability tools (e.g., SHAP analysis). 51 51 * Facilitates decision-making for clinicians by linking annotations to standardized biomedical ontologies (SNOMED, HPO). 52 52 53 -Neurodiagnoses provides two complementary AI-driven diagnostic approaches: 43 +Neurodiagnoses provides **two complementary AI-driven diagnostic approaches**: 54 54 55 -1. Traditional Probabilistic Diagnosis 45 +1. **Probabilistic Diagnosis** 46 + * AI assigns probability scores to multiple possible diagnoses based on biomarker, imaging, and clinical data. 47 + * Useful for differential diagnosis and treatment decision-making. 56 56 57 -* AI provides multiple possible diagnoses, each assigned a probability percentage based on biomarker, imaging, and clinical data. 58 -* Example Output: 49 +2. **Tridimensional Diagnosis** 50 + * Diagnoses are structured based on: 51 + - **(1) Etiology** (genetic, autoimmune, metabolic, infectious). 52 + - **(2) Molecular Biomarkers** (amyloid-beta, tau, inflammatory markers, EEG patterns). 53 + - **(3) Neuroanatomoclinical Correlations** (brain atrophy, connectivity alterations). 54 + * This approach enables precise disease subtyping and biologically meaningful classification, particularly useful for tracking progression over time. 59 59 60 -{{{75% Alzheimer's Disease 61 -20% Lewy Body Dementia 62 -5% Vascular Dementia 63 -}}} 64 -* Useful for differential diagnosis and treatment decision-making. 56 +Both systems will be offered for every patient case, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification. 65 65 66 - 2. TridimensionalDiagnosis58 +== **Disease Prediction and Biomarker Estimation** == 67 67 68 -* Diagnoses are structured based on: 69 -(1) Etiology (genetic, autoimmune, metabolic, infectious) 70 -(2) Molecular Biomarkers (amyloid-beta, tau, inflammatory markers, EEG patterns) 71 -(3) Neuroanatomoclinical Correlations (brain atrophy, connectivity alterations) 72 -* This approach enables precise disease subtyping and biologically meaningful classification. 60 +Neurodiagnoses is also implementing **biomarker prediction and disease progression modeling**, using advanced machine learning techniques: 73 73 74 -For every patient case, both systems will be offered, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification. 62 +* **Biomarker Prediction:** 63 + - Estimation of fluid-based and neuroimaging biomarkers without invasive testing. 64 + - Multi-modal machine learning models for predicting molecular and clinical markers. 75 75 66 +* **Disease Progression Modeling:** 67 + - AI-driven forecasts for neurodegenerative disease evolution. 68 + - Probabilistic disease conversion models (e.g., MCI to AD, Parkinson's prodromal phases). 69 + - Survival models and risk stratification for precision medicine applications. 76 76 77 77 == **The case of neurodegenerative diseases** == 78 78 ... ... @@ -82,25 +82,18 @@ 82 82 83 83 * ((( 84 84 **Axis 1: Etiology** 85 - 86 86 * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 87 87 * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 88 88 * //Tests//: Genetic testing, lifestyle, and cardiovascular screening. 89 - 90 - 91 91 ))) 92 92 * ((( 93 93 **Axis 2: Molecular Markers** 94 - 95 95 * //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. 96 96 * //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. 97 97 * //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). 98 - 99 - 100 100 ))) 101 101 * ((( 102 102 **Axis 3: Neuroanatomoclinical** 103 - 104 104 * //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. 105 105 * //Examples//: Hippocampal atrophy correlating with memory deficits. 106 106 * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. ... ... @@ -110,7 +110,7 @@ 110 110 111 111 This system enhances: 112 112 113 -* **Research**: By stratifying patients, reduc escohort heterogeneity in clinical trials.100 +* **Research**: By stratifying patients, reducing cohort heterogeneity in clinical trials. 114 114 * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. 115 115 116 116 == How to Contribute == ... ... @@ -118,6 +118,8 @@ 118 118 * Access the `/docs` folder for guidelines. 119 119 * Use `/code` for the latest AI pipelines. 120 120 * Share feedback and ideas in the wiki discussion pages. 108 +* Join our [[Community on EBRAINS>>https://community.ebrains.eu/_ideas/-OJHTZrpKrrrkx-u0djj/about]] 109 +* Join the [[Discussion Forum at GitHub>>https://github.com/Fundacion-de-Neurociencias/neurodiagnoses/discussions]] 121 121 122 122 == Key Objectives == 123 123 ... ... @@ -124,17 +124,17 @@ 124 124 * Develop interpretable AI models for diagnosis and progression tracking. 125 125 * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. 126 126 * Foster collaboration among neuroscientists, AI researchers, and clinicians. 116 +* Provide a dual diagnostic system: 117 + ** Probabilistic Diagnosis – AI assigns multiple traditional possible diagnoses with probability percentages. 118 + ** Tridimensional Diagnosis – AI structures diagnoses based on etiology, biomarkers, and neuroanatomical correlations. 119 +* Implement disease prediction models for neurodegenerative conditions. 120 +* Predict biomarkers from non-invasive data sources. 127 127 128 128 == Who has access? == 129 129 130 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 124 +We welcome contributions from the global community. Join us as we transform CNS diagnostics and drive precision medicine forward through a collaborative, open-source approach. Let’s build the future of neurological diagnostics together! 131 131 ))) 132 132 133 - 134 - 135 - 136 - 137 - 138 138 (% class="col-xs-12 col-sm-4" %) 139 139 ((( 140 140 {{box title="**Contents**"}} ... ... @@ -153,3 +153,4 @@ 153 153 * [[to-do-list>>to-do-list]] 154 154 ))) 155 155 ))) 145 +